|
AU5052400A
|
|
Porcine hepatocytes for use in treatment of disorders characterized by insufficent liver function
|
|
AU6234600A
|
|
Muscle cells and their use in cardiac repair
|
|
CA2364279A1
|
|
Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent
|
|
AU1637700A
|
|
Modified cells and methods for inhibiting hyperacute rejection of xenogenic transplants
|
|
AU6169899A
|
|
Porcine mesencephalic cells and their use in treatment of neurological deficits due to neurodegenerative diseases
|
|
AU6276899A
|
|
Transplantation of neural cells for the treatment of ischemic damage due to stroke
|
|
AU1096400A
|
|
Determining resistance to treatment for hepatitis c virus
|
|
CA2341755A1
|
|
Cells expressing immunoregulatory molecules and uses therefor
|
|
EP1092010A2
|
|
Porcine spinal cord cells and their use in spinal cord repair
|
|
AU9718598A
|
|
Genetically modified cells for use in transplantation
|
|
US6444205B2
|
|
Transplantation of neural cells for the treatment of chronic pain or spasticity
|
|
US6284245B1
|
|
Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders
|
|
US6713245B2
|
|
Methods for storing neural cells such that they are suitable for transplantation
|
|
US6521448B1
|
|
Porcine MHC class I genes and uses thereof
|
|
EP0910394A1
|
|
Method for providing pathogen-free porcine tissue suitable for human transplantation
|
|
AU5874896A
|
|
Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function
|
|
CA2217131A1
|
|
Modified cells and methods for inhibiting xenograft rejection
|
|
CA2203032A1
|
|
Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
|
|
US5919449A
|
|
Porcine cardiomyocytes and their use in treatment of insufficient cardiac function
|
|
AU2587995A
|
|
Modified cells and methods for inhibiting hyperacute rejection of xenogeneic transplants
|
